Education
About Us
Working with TipRanks
Follow Us
Prophase Labs (PRPH)
:PRPH
PRPH Stock Chart & Stats
$0.18
-$0.13(-18.06%)
At close: 4:00 PM EST
$0.18
-$0.13(-18.06%)
Day’s Range― - ―
52-Week Range$0.11 - $0.93
Previous CloseN/A
Volume469.10K
Average Volume (3M)2.82M
Market Cap
$5.30M
Enterprise Value$26.30M
Total Cash (Recent Filing)$405.00K
Total Debt (Recent Filing)$7.68M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Apr 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding46,179,016
10 Day Avg. Volume5,991,178
30 Day Avg. Volume2,820,906
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.96
Price to Sales (P/S)2.13
P/FCF Ratio-0.78
Enterprise Value/Market Cap4.96
Enterprise Value/Revenue24.42
Enterprise Value/Gross Profit12.76
Enterprise Value/Ebitda-1.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Prophase Labs News
PRPH FAQ
What was Prophase Labs’s price range in the past 12 months?
Prophase Labs lowest stock price was $0.11 and its highest was $0.93 in the past 12 months.
What is Prophase Labs’s market cap?
Prophase Labs’s market cap is $5.30M.
When is Prophase Labs’s upcoming earnings report date?
Prophase Labs’s upcoming earnings report date is Apr 01, 2026 which is in 106 days.
How were Prophase Labs’s earnings last quarter?
Prophase Labs released its earnings results on Nov 19, 2025. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.16.
Is Prophase Labs overvalued?
According to Wall Street analysts Prophase Labs’s price is currently Overvalued.
Does Prophase Labs pay dividends?
Prophase Labs pays a Notavailable dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Prophase Labs dividends here
What is Prophase Labs’s EPS estimate?
Prophase Labs’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prophase Labs have?
Prophase Labs has 46,179,016 shares outstanding.
What happened to Prophase Labs’s price movement after its last earnings report?
Prophase Labs reported an EPS of -$0.16 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.538%.
Which hedge fund is a major shareholder of Prophase Labs?
Currently, no hedge funds are holding shares in PRPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prophase Labs
Prophase Labs, Inc. (PRPH) is a biotechnology company focused on developing and commercializing innovative therapies for infectious diseases and other medical conditions. The company operates primarily in the healthcare and life sciences sectors, with a strong emphasis on antiviral and therapeutic solutions. Prophase Labs is known for its proprietary product offerings, including treatments for respiratory viruses and other infectious agents, leveraging cutting-edge research and development in the field of virology.
PRPH Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted several promising developments, such as the Crown Medical collections, potential partnerships for the esophageal cancer test, and a turnaround in the Nebula Genomics business. However, these positives were counterbalanced by significant challenges, including financial constraints, a declining stock price, and the need for a reverse stock split to maintain Nasdaq compliance. The company is actively pursuing strategic initiatives to address these issues and improve shareholder value.View all PRPH earnings summariesTechnical Analysis
Ownership Overview
9.29%
Insiders
1.63% Mutual Funds
3.01% Other Institutional Investors
85.39% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---